Researchers investigated the impact of adding community scheduled malaria screening and treatment (CSST) with artemether-lumefantrine by community health workers (CHWs) to standard intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) on maternal and infant health. They randomized villages in Burkina Faso, The Gambia, and Benin to receive CSST plus IPTp-SP or IPTp-SP alone in this 2-arm cluster-randomized, controlled trial. Outcomes suggested no reduction in malaria in pregnancy with the CSST addition to existing IPTp-SP strategies. They identified increasing the number of IPTp-SP doses given during pregnancy as a priority.